Emerging cancer therapeutic opportunities by inhibiting mitotic kinases

Current Opinion in Pharmacology

Volumn 8, Issue 4, 2008, Pages 375-383

  Pérez de Castro, Ignacio ^a   de Cárcer, Guillermo ^a   Montoya, Guillermo ^a   Malumbres, Marcos ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; AT 7519; AT 9283; AURORA KINASE INHIBITOR; AZD 1152; BI 2536; CINCREASIN; CYC 116; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; GSK 461364; HESPERADIN; HMN 214; MLN 8054; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; ON 01910; P 276 00; PACLITAXEL; PHA 739358; PHOSPHOTRANSFERASE; POLO LIKE KINASE 1; R 547; R 763; SNS 314; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; ZK 304709;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER RESISTANCE; CHROMOSOME SEGREGATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MITOSIS INHIBITION; MULTIPLE MYELOMA; NAUSEA; NEOPLASM; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CDC2 PROTEIN KINASE; GENES, CDC; HUMANS; MITOTIC SPINDLE APPARATUS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 51449108571     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.06.013     Document Type: Review

References (53)

1. Malumbres M., and Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 17 (2007) 60-65
2. Perez de Castro I., de Carcer G., and Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 28 (2007) 899-912. A comprehensive review of cancer-associated mutations in mitotic regulators. These data suggest a relevant deregulation of the SAC in multiple tumor types and reveals multiple mitotic kinases with specific mutations in cancer.
3. Taylor S., and Peters J.M. Polo and Aurora kinases: lessons derived from chemical biology. Curr Opin Cell Biol 20 (2008) 77-84. The use of specific small molecule inhibitors in research has produced relevant data on new functions for specific mitotic kinases, which are reviewed in this reference.
4. Malumbres M., Pevarello P., Barbacid M., and Bischoff J.R. CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol Sci 29 (2008) 16-21
5. Musacchio A., and Salmon E.D. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8 (2007) 379-393
6. Wood K.W., Cornwell W.D., and Jackson J.R. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 1 (2001) 370-377
7. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4 (2004) 253-265
8. Li T., Inoue A., Lahti J.M., and Kidd V.J. Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development. Mol Cell Biol 24 (2004) 3188-3197
9. ••] describe the requirement for CDK11 and CDK1 in the cell cycle using genetic ablation in the mouse. Given the attractiveness of CDKs for drug discovery, these results should be considered when analyzing the more relevant targets within the CDK family.
10. Yokoyama H., Gruss O.J., Rybina S., Caudron M., Schelder M., Wilm M., Mattaj I.W., and Karsenti E. Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate. J Cell Biol 180 (2008) 867-875
11. Hu D., Valentine M., Kidd V.J., and Lahti J.M. CDK11(p58) is required for the maintenance of sister chromatid cohesion. J Cell Sci 120 (2007) 2424-2434
12. Chandramouli A., Shi J., Feng Y., Holubec H., Shanas R.M., Bhattacharyya A.K., Zheng W., and Nelson M.A. Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice. Carcinogenesis 28 (2007) 2028-2035
13. Vassilev L.T., Tovar C., Chen S., Knezevic D., Zhao X., Sun H., Heimbrook D.C., and Chen L. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. PNAS 103 (2006) 10660-10665
14. Hochegger H., Dejsuphong D., Sonoda E., Saberi A., Rajendra E., Kirk J., Hunt T., and Takeda S. An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells. J Cell Biol 178 (2007) 257-268. Along with [13], a detailed analysis of CDK1 functions in the cell cycle using specific small molecule inhibitors or chemical genetics.
15. de Carcer G., Perez de Castro I., and Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14 (2007) 969-985
16. Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 104 (2007) 4106-4111
17. •] report the first description of a selective Aurora A inhibitor.
18. Girdler F., Gascoigne K.E., Eyers P.A., Hartmuth S., Crafter C., Foote K.M., Keen N.J., and Taylor S.S. Validating Aurora B as an anti-cancer drug target. J Cell Sci 119 (2006) 3664-3675
19. •] compare the cellular defects caused by the inhibition of the two major Aurora kinases, Aurora A and B, suggesting distinct mechanisms for mitotic arrest. Inhibition of both Aurora A and B is undistinguishable from the phenotype induced by Aurora B deficiency, suggesting not further advantages of targeting both proteins at least in these cellular systems.
20. Gautschi O., Heighway J., Mack P.C., Purnell P.R., Lara Jr. P.N., and Gandara D.R. Aurora kinases as anticancer drug targets. Clin Cancer Res 14 (2008) 1639-1648
21. Sasai K., Parant J.M., Brandt M.E., Carter J., Adams H.P., Stass S.A., Killary A.M., Katayama H., and Sen S. Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene 27 (2008) 4122-4127. The early embryonic lethality in the absence of Aurora A suggests putative toxic effects of inhibiting Aurora A in vivo.
22. Burkard M.E., Randall C.L., Larochelle S., Zhang C., Shokat K.M., Fisher R.P., and Jallepalli P.V. Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A 104 (2007) 4383-4388. A detailed analysis of PLK1 functions in the cell cycle using chemical genetics.
23. Wu Z.Q., and Liu X. Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing. Proc Natl Acad Sci U S A 105 (2008) 1919-1924
24. Trenz K., Errico A., and Costanzo V. Plx1 is required for chromosomal DNA replication under stressful conditions. EMBO J 27 (2008) 876-885
25. Lei M., and Erikson R.L. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene 27 (2008) 3935-3943
26. Johnson E.F., Stewart K.D., Woods K.W., Giranda V.L., and Luo Y. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 46 (2007) 9551-9563. An intense exercise to find differences in the kinase domain among the PLK family members and their implications in the search for and evaluation of specific inhibitors.
27. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM: The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007, 17:304-315.
28. ••] describe a potent and specific inhibitor of PLK1 and its use in experimental therapy of cancer. This drug is currently in clinical trials (Table 1).
29. Rodrigues-Martins A., Riparbelli M., Callaini G., Glover D.M., and Bettencourt-Dias M. Revisiting the role of the mother centriole in centriole biogenesis. Science 316 (2007) 1046-1050
30. Kleylein-Sohn J., Westendorf J., Le Clech M., Habedanck R., Stierhof Y.D., and Nigg E.A. Plk4-induced centriole biogenesis in human cells. Dev Cell 13 (2007) 190-202
31. Ko M.A., Rosario C.O., Hudson J.W., Kulkarni S., Pollett A., Dennis J.W., and Swallow C.J. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 37 (2005) 883-888
32. Fedorov O., Marsden B., Pogacic V., Rellos P., Muller S., Bullock A.N., Schwaller J., Sundstrom M., and Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A 104 (2007) 20523-20528
33. Gold M.G., Barford D., and Komander D. Lining the pockets of kinases and phosphatases. Curr Opin Struct Biol 16 (2006) 693-701. A very exciting proposal to study additional pocket domains within critical kinases and phosphatases to reach specific inhibition without the need to target the catalytic domain.
34. Anderson K., Yang J., Koretke K., Nurse K., Calamari A., Kirkpatrick R.B., Patrick D., Silva D., Tummino P.J., Copeland R.A., et al. Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry 46 (2007) 10287-10295
35. ••] provide critical data for understanding the regulation of Aurora A and B kinases and to evaluate the design of new specific inhibitors.
36. Hanisch A., Wehner A., Nigg E.A., and Sillje H.H. Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell 17 (2006) 448-459
37. Garcia-Alvarez B., de Carcer G., Ibanez S., Bragado-Nilsson E., and Montoya G. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization. Proc Natl Acad Sci U S A 104 (2007) 3107-3112
38. •] provide structural and functional information to analyze the relevance of the polo-box domain in PLK1 function, and to demonstrate significant differences in this region among the PLK family members.
39. Reindl W., Yuan J., Krämer A., Strebhardt K., and Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem. & Biol. 15 (2008) 459-466
40. Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., and Golemis E.A. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 129 (2007) 1351-1363
41. Sabbattini P., Canzonetta C., Sjoberg M., Nikic S., Georgiou A., Kemball-Cook G., Auner H.W., and Dillon N. A novel role for the Aurora B kinase in epigenetic marking of silent chromatin in differentiated postmitotic cells. EMBO J 26 (2007) 4657-4669
42. Larochelle S., Merrick K.A., Terret M.E., Wohlbold L., Barboza N.M., Zhang C., Shokat K.M., Jallepalli P.V., and Fisher R.P. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 25 (2007) 839-850. A detailed analysis of CDK7 functions in the cell cycle using chemical genetics.
43. Nakajima H., Yonemura S., Murata M., Nakamura N., Piwnica-Worms H., and Nishida E. Myt1 protein kinase is essential for Golgi and ER assembly during mitotic exit. J Cell Biol 181 (2008) 89-103
44. Jelluma N., Brenkman A.B., van den Broek N.J., Cruijsen C.W., van Osch M.H., Lens S.M., Medema R.H., and Kops G.J. Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment. Cell 132 (2008) 233-246
45. Riefler G.M., Dent S.Y., and Schumacher J.M. Tousled-mediated activation of the Aurora B kinase does not require tousled kinase activity in vivo. J Biol Chem 283 (2008) 12763-12768
46. Dai J., Sullivan B.A., and Higgins J.M. Regulation of mitotic chromosome cohesion by Haspin and Aurora B. Dev Cell 11 (2006) 741-750
47. Rosasco-Nitcher S.E., Lan W., Khorasanizadeh S., and Stukenberg P.T. Centromeric Aurora-B activation requires TD-60, microtubules, and substrate priming phosphorylation. Science 319 (2008) 469-472
48. Kokuryo T., Senga T., Yokoyama Y., Nagino M., Nimura Y., and Hamaguchi M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Cancer Res 67 (2007) 9637-9642
49. Boshoff H.I., and Dowd C.S. Chemical genetics: an evolving toolbox for target identification and lead optimization. Prog Drug Res 64 (2007) 51-77
50. Whitehurst A.W., Bodemann B.O., Cardenas J., Ferguson D., Girard L., Peyton M., Minna J.D., Michnoff C., Hao W., Roth M.G., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446 (2007) 815-819. A paclitaxel-dependent synthetic lethal screen to identify gene targets that specifically reduce cell viability in the presence of this mitotic poison. Several of these targets sensitize lung cancer cells to paclitaxel concentrations 1000-fold lower than otherwise required for a significant response, suggesting new avenues to improve the clinical efficacy of current or future mitotic drugs.
51. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26 (2008) 127-132
52. Elia A.E., Rellos P., Haire L.F., Chao J.W., Ivins F.J., Hoepker K., Mohammad D., Cantley L.C., Smerdon S.J., and Yaffe M.B. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 115 (2003) 83-95
53. Kothe M., Kohls D., Low S., Coli R., Cheng A.C., Jacques S.L., Johnson T.L., Lewis C., Loh C., Nonomiya J., et al. Structure of the catalytic domain of human polo-like kinase 1. Biochemistry 46 (2007) 5960-5971